sphingoid, fatty acid, galactose and sulphate, and are thought to be present on the outer leaflets of biological membranes in various tissues, such as brain, kidney, liver, and gastrointestinal tract. 1 They are also present in serum lipoproteins. 1, 3 An immunofluorescence study showed that sulphatides in rat kidneys were distributed predominantly on the luminal (apical) membrane of the thick ascending limb. 2 We have been investigating the possible involvement of sulphatides in thrombosis/atherosclerosis since the late 1980s. We have found that sulphatide levels are increased in the sera of animal models for familial hypercholesterolemia, and that they prolong blood-coagulation time and bleeding time. 3, 4, 5, 6 These results led us to the hypothesis that sulphatides might be natural anticoagulant/antithrombotic agents in blood. 7 Cardiovascular disease (CVD) is a serious problem for patients with kidney dysfunction.
Such patients are more likely to die of CVD than to develop kidney failure. Mortality due to CVD is 10 to 30 times higher in these patients than in the general population.
Thus, CVD in patients with end-stage renal failure (ESRF) is a world-wide social and health problem, and many risk factors have been proposed. 8, 9, 10 Previously, we established a high-throughput method for the analysis of lysosulphatides (LSs) as a 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w   6   6 measure of the level of sulphatides in a small amount of sera, using matrix-assisted laser desorption ionisation-time of flight mass spectrometry (MALDI-TOF MS).
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Subsequently, using this method, we demonstrated that the level of serum sulphatides was gradually decreased in parallel with kidney dysfunction and found a close correlation between low serum sulphatides levels and the high incidence of CVD in patients with ESRF. 12 However, the precise mechanism underlying this decrease in serum sulphatide levels with kidney dysfunction remains unknown. As a first step to elucidate this mechanism, we investigated the amounts and compositions of sulphatides in major serum sulphatide-producing organs in the kidney dysfunction state. For this purpose, we employed mouse protein overload nephropathy as a kidney dysfunction model, because this animal model develops reproducible kidney dysfunction owing to proximal tubular injuries in short time.
13, 14

MATERIALS AND METHODS
Animal Studies
Male mice on an Sv/129 genetic background were used as described elsewhere.
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Mice (18 weeks) were treated in a specific pathogen-free facility according to the Shinshu University and National Institutes of Health animal care guidelines and the Accreditation of Laboratory Animal Care guidelines. Protein overload nephropathy was Under general anaesthesia, mice were killed by exsanguinations for analysis on days 4
and 10. The numbers of mice subjected to analysis were as follows: day 0 group, normal mice, n = 4; day 4 group, n = 6; day 10 group, n = 8. Sera, livers, small intestines, and kidneys were removed and stored at -80°C until analysis.
Quantitation and qualitation of sulphatides
Sulphatides were extracted from specimens using a hexane-isopropanol mixture. 18 After chemically converting sulphatides to LSs (sulphatides without fatty acids), samples were desalted by Mono-tip C18 tips (GL Sciences Inc. Tokyo, Japan) and analysed by matrix-assisted laser desorption ionisation time-of-flight mass spectrometry using a Voyager Elite XL Biospectrometry Workstation (PerSeptive Biosystems, Framingham, MA) in the negative ion mode, as described previously. 11, 12, 16, 17 This method allowed quantitation of serum sulphatides from 100 serum specimens within one working day. show statistical significance. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 proportions of LS-d18:2, LS-d18:0, LS-t18:0 and LS-d20:1 were commonly observed in these three sample types. The LS composition of sulphatides in sera was very similar to that in livers and partly similar to that in small intestines. Serum sulphatides are present as a major glycosphingolipid in serum lipoproteins. 3 It is well known that most serum lipoproteins originate from livers (approximately 90%), with the rest being derived from the small intestines (approximately 10%), as confirmed by sphingoid analysis of sulphatides. 3 Our results indicate that the compositions of molecular species of LSs converted from sulphatides reflect the locations where serum sulphatides are probably produced. LSs in kidneys were predominantly composed of LS-d18:1 (60.0±0.7%). The composition of LSs in kidneys is thought to be specific to this organ. Judging from the obvious differences in the levels of different molecular species of sulphatides between kidneys and sera, livers or small intestines, there seemed to be no metabolic correlation between the sulphatides in the kidneys and those in lipoprotein-related organs. The levels of sulphatides in normal mice were determined to be 1598.5±60.3 pmol/ml in sera, 31.3±1.1 pmol/mg in livers, 60.1±1.1 pmol/mg in small intestines, and advanced, the levels of sulphatides in livers and small intestines were significantly decreased in a similar manner to those in sera (Fig. 2) . No compositional differences in LSs were observed among the control group (day 0), the day 4 group and the day 10 group, for all three specimen types (data not shown). These results suggest that the reduction in the levels of sulphatides in sera is caused by renal dysfunction.
RESULTS AND DISCUSSION
Furthermore, this reduction is related to the reduction in the levels of sulphatides in the lipoprotein-producing organs, namely livers and small intestines, because both the LS species ( Fig. 1 ) and the rates of decreases are similar among these three specimens (Fig.   2 ). On the other hand, the levels of sulphatides in kidneys were moderately increased without remarkable differences in the composition of LSs with progression of the disease. Using mouse and rat models of tubulointerstitial injury, Shikata's group reported that sulphatides were L-selectin ligands in kidneys, and relocated from the distal tubules to the peritubular capillaries with possible new synthesis of sulphatides in kidneys, where many infiltrating mononuclear cells, which contain sulphatides, were observed. 19, 20 In the present study, a small but significant number of infiltrating monocytes was also observed by pathological examination of the kidneys of mice with renal dysfunction (data not shown). However, the numbers of monocytes seemed to be too small to explain the increase in the levels of sulphatides. More detailed examinations concerning the regulation of renal sulphatides will be needed in the future.
Various studies have suggested that sulphatides are involved in renal functions, such as urine production/urine concentration 1 . The renal dysfunction caused by injection of BSA might somehow lead to an increment in the level of sulphatides in kidneys to compensate for the loss of kidney function. Recently, Nagai et al reported that the addition of gluconeogenic renal nutritional substrate (glutamine) to medium containing isolated renal tubules from rats accelerated the turnover rate of sulphatides to twice that of controls. 21 In our experiment, daily injection of BSA might supply enough amino acids to affect the synthesis of sulphatides, and thus, might increase the amounts in kidneys.
It is suggested that the reduction in the levels of serum sulphatides found in patients with ESRF is not due to long-term haemodialysis, but probably due to a reduction in the levels of sulphatides in livers and small intestines where serum sulphatides are supposed to be produced and supplied to the blood stream as components of serum lipoproteins. The present experiment, using mice with protein overload nephropathy, indicated that kidney dysfunction affects the levels of sulphatides in lipoprotein-producing organs, such as livers and small intestines, and lowers the level of sulphatides in sera. It remains to be studied how kidney dysfunction affects the levels of sulphatides in livers and small intestines. A current working hypothesis is that kidney dysfunction might influence the expression levels of sulphatides-metabolic enzymes in livers and small intestines. Studies concerning the expression levels of these enzymes are currently underway.
The present study suggests that the reduction in the levels of serum sulphatides found in patients with kidney dysfunction might be due to a reduction in the levels of sulphatides in livers and small intestines, where serum sulphatides are probably produced and supplied to the blood stream as components of serum lipoproteins. Since serum sulphatides are thought to be a natural anti-thrombotic agent in blood 3, 4, 5, 6 , low levels of sulphatides may lead to the development of CVD in patients with kidney dysfunction. We believe that elucidation of the mechanism underlying the decrease in 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w 13 13 serum sulphatide levels associated with kidney dysfunction might contribute to an understanding of the relationship between kidney dysfunction and the high incidence of CVD in such patients in the future.
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